Literature DB >> 15248210

Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.

Gerrit Jansen1, Joost van der Heijden, Ruud Oerlemans, Willem F Lems, Ilan Ifergan, Rik J Scheper, Yehuda G Assaraf, Ben A C Dijkmans.   

Abstract

OBJECTIVE: To investigate whether interactions of sulfasalazine (SSZ) with reduced folate carrier (RFC), the dominant cell membrane transporter for natural folates and methotrexate (MTX), may limit the efficacy of combination therapy with MTX and SSZ in patients with rheumatoid arthritis.
METHODS: Human RFC-(over)expressing CEM cells of T cell origin were used to analyze the effect of SSZ on the RFC-mediated cellular uptake of radiolabeled MTX and the natural folate leucovorin. Moreover, both cells with and those without acquired resistance to SSZ were used to assess the antiproliferative effects of MTX in combination with SSZ.
RESULTS: Transport kinetic analyses revealed that SSZ was a potent noncompetitive inhibitor of RFC-mediated cellular uptake of MTX and leucovorin, with mean +/- SD K(i) (50% inhibitory concentration) values of 36 +/- 6 microM and 74 +/- 7 microM, respectively. Consistent with the inhibitory interaction of SSZ with RFC, a marked loss of MTX efficacy was observed when MTX was coadministered with SSZ: up to 3.5-fold for CEM cells in the presence of 0.25 mM of SSZ, and >400-fold for SSZ-resistant cells in the presence of 2.5 mM of SSZ. Importantly, along with diminished efficacy of MTX, evidence for cellular folate depletion was obtained by the demonstration of an SSZ dose-dependent decrease in leucovorin accumulation.
CONCLUSION: At clinically relevant plasma concentrations, interactions of SSZ with RFC provide a biochemical rationale for 2 important clinical observations: 1) the onset of (sub)clinical folate deficiency during SSZ treatment, and 2) the lack of additivity/synergism of the combination of SSZ and MTX when these disease-modifying antirheumatic drugs are administered simultaneously. Thus, when considering use of these drugs in combination therapies, the present results provide a rationale both for the use of folate supplementation and for spacing administration of these drugs over time.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248210     DOI: 10.1002/art.20375

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  26 in total

Review 1.  Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management.

Authors:  Ashima Makol; Kerry Wright; Shreyasee Amin
Journal:  Drugs       Date:  2011-10-22       Impact factor: 9.546

Review 2.  Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know.

Authors:  Megan L Krause; Shreyasee Amin; Ashima Makol
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-10       Impact factor: 5.346

3.  SLC19A1 Is an Importer of the Immunotransmitter cGAMP.

Authors:  Christopher Ritchie; Anthony F Cordova; Gaelen T Hess; Michael C Bassik; Lingyin Li
Journal:  Mol Cell       Date:  2019-05-21       Impact factor: 17.970

Review 4.  Intestinal absorption of water-soluble vitamins in health and disease.

Authors:  Hamid M Said
Journal:  Biochem J       Date:  2011-08-01       Impact factor: 3.857

5.  Pneumocystis carinii activates the NF-kappaB signaling pathway in alveolar epithelial cells.

Authors:  Jing Wang; Francis Gigliotti; Sanjay Maggirwar; Carl Johnston; Jacob N Finkelstein; Terry W Wright
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

6.  Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease.

Authors:  Barrett G Levesque; Sunanda V Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

7.  Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.

Authors:  Hilary A Capell; Rajan Madhok; Duncan R Porter; Robin A L Munro; Iain B McInnes; John A Hunter; Malcolm Steven; Asad Zoma; Elaine Morrison; Martin Sambrook; Fat Wui Poon; Rosemary Hampson; Fiona McDonald; Ann Tierney; Neil Henderson; Ian Ford
Journal:  Ann Rheum Dis       Date:  2006-08-22       Impact factor: 19.103

8.  Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.

Authors:  M Schoels; T Kapral; T Stamm; J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2007-02-16       Impact factor: 19.103

9.  Serum homocysteine level in patients with ankylosing spondylitis.

Authors:  Bedriye Mermerci Başkan; Filiz Sivas; Lale Akbulut Aktekin; Yasemin Pekin Doğan; Kürşat Ozoran; Hatice Bodur
Journal:  Rheumatol Int       Date:  2009-03-15       Impact factor: 2.631

10.  Effect of folic acid on methotrexate induction of sulfotransferases in rats.

Authors:  Sangita Maiti Dutta; Smarajit Maiti; Guangping Chen
Journal:  Drug Metab Lett       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.